抗体偶联药物治疗乳腺癌的研究进展

Advances in antibody-drug conjugates in the treatment of breast cancer

抗体偶联药物是一种很有潜力的新型肿瘤靶向药物,具有抗体药物选择性强和化疗药物活性高的优势。近年来,在乳腺癌领域,通过选择不同的肿瘤细胞表面靶点和小分子细胞毒性物质,再加上连接方式的进步,对复发/转移性实体肿瘤有较好治疗效果的新型抗体偶联药物不断研发上市,代表着个体化精准治疗的快速发展。目前,在全球范围内已有3种抗体偶联药物获批治疗乳腺癌,除曲妥珠单抗-美坦新偶联物(T-DM1)和曲妥珠单抗-依沙替康衍生物(DS-8201a)用于治疗HER-2阳性乳腺癌外,三阴性乳腺癌也可以从Sacituzumab govitecan获益。同时,一些抗体偶联药物与内分泌治疗、免疫检查点抑制剂联合应用的临床研究也正在开展。本文就近年来应用于乳腺癌治疗的抗体偶联药物的研究进展作一综述。

Antibody-drug conjugates is a kind of new potential tumor targeted drugs,with the advantages of both high selectivity of the antibody drug and the activity of chemotherapy drugs.In the field of breast cancer,with choosing different targets on the surface of the tumor cell and small molecular cell toxicity,and the advance of the connection method,a lot of novel ADCs continuously research and develop to enter the market for entity/metastatic tumors,which represents the rapid development of individualized precision therapy.Currently,there are three antibody-drug conjugates have been approved for the treatment of breast cancer in the world.In addition to the Trastuzumab emtansine(T-DM1)and Trastuzumab deruxtecan(DS-8201a)used for the treatment of HER-2 positive breast cancer,triple-negative breast cancer can also benefit from Sacituzumab govitecan.At the same time,some clinical studies on the combination of antibody-drug conjugates with endocrine therapy and immunocheckpoint inhibitors are being carried out.This paper reviews the recent development of antibody-conjugated drugs for the treatment of breast cancer.